GlaxoSmithKline (GSK) Pharmaceuticals Limited belongs to one of the oldest pharmaceutical companies in India. With its headquarters in Mumbai, Maharashtra, it is also the Indian subsidiary of the GlaxoSmithKline plc, a British multinational pharmaceutical company located in Brentford, England.
In April 2020, GSK joined forces with rival Sanofi in the COVID-19 vaccine development. While Sanofi developed the antigen, the adjuvant, which is the key component of the vaccine was developed by GSK to boost the immune response of the antigen. Sold under the brand name VidPrevtyn Beta, it was approved for medical use in the EU in November 2022.
Following this success, the company's shift to prioritize vaccines was focused into four areas: infectious diseases, HIV, oncology, and immunology. Its latest entry into the market was Shingrix, a vaccine against shingles, partnering with veteran Bollywood actor Amitabh Bachchan for promoting and increasing awareness through ad campaigns.
Bringing Indian pharma to the forefront
Recently, the company’s primary focus has been in science relative to immunity and human genetics. This has been made possible through the application of highly sophisticated computer systems or deep artificial intelligence. Further, with an increase in the global number of studies in clinical oncology over the last few years, GSK’s performance reflected unparalleled success in the area of research and development with four assets of the company progressing into the phase II and III of the clinical study. What is more, approval for medicines for HIV treatment including antiretrovirals, influenza and respiratory disorders were also received. Clinical trials are research studies that involve people.Product portfolio
In the area of pharmaceuticals, GSK produces medications to combat several major diseases. The spectrum ranges from the increasing number of asthmatic and diabetic cases to infections, cancers and problems related to mental health. With regard to consumer health products and with the rise in prevalence of oral disorders, predominantly in India, GSK has established itself as one of the world’s leading sensitivity brands that has created a significant impact in the global, as well as Indian toothpaste segment. Some of the other leading and recognized products are Crocin, one India’s leading analgesics in the non-prescription category and Otrivin, a nasal decongestant.A shift in strategy - human genetics to vaccines
GSK belongs to the leading global players in the vaccine market based on revenue. The global vaccine market is projected to experience an exponential growth in the years to come, compounded with the recent global COVID-19 pandemic. The world’s leading vaccine companies were in fierce competition in the race to develop the vaccine for coronavirus.In April 2020, GSK joined forces with rival Sanofi in the COVID-19 vaccine development. While Sanofi developed the antigen, the adjuvant, which is the key component of the vaccine was developed by GSK to boost the immune response of the antigen. Sold under the brand name VidPrevtyn Beta, it was approved for medical use in the EU in November 2022.
Following this success, the company's shift to prioritize vaccines was focused into four areas: infectious diseases, HIV, oncology, and immunology. Its latest entry into the market was Shingrix, a vaccine against shingles, partnering with veteran Bollywood actor Amitabh Bachchan for promoting and increasing awareness through ad campaigns.
